Used primarily in the treatment of chronic immune thrombocytopenia (ITP), it works by inhibiting spleen tyrosine kinase (SYK), which plays a role in the immune response that leads to platelet destruction. This helps in increasing platelet counts in patients who have not responded adequately to other treatments. Additionally, it is being investigated for its potential in treating other autoimmune diseases and certain types of cancer, where SYK inhibition could be beneficial. Its application in these areas is based on its ability to modulate immune system activity and reduce inflammation.